Evidence map›Paper›PMID 27655708›Full record

ArticleOncotarget2016

Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation.

Yan Li, Yanmei Wang, Kai Niu, Xiewan Chen, Liqin Xia, Dingxi Lu, Rui Kong, Zhengtang Chen, Yuzhong Duan, Jianguo Sun

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yan LiDepartment of Oncology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Yanmei WangDepartment of Oncology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Kai NiuDepartment of Oncology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Xiewan ChenMedical English Department, College of Basic Medicine, Third Military Medical University, Chongqing, 400038, China.
Liqin XiaDepartment of Oncology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Dingxi LuMedical English Department, College of Basic Medicine, Third Military Medical University, Chongqing, 400038, China.
Rui KongDepartment of Oncology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Zhengtang ChenDepartment of Oncology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Yuzhong DuanDepartment of Oncology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Jianguo SunDepartment of Oncology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Xinqiao Hospital · CNArmy Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAcquired resistance is a bottleneck that restricts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) for lung cancer. Ginsenoside Rg3 is an antiangiogenic agent which can down-regulate the expressions of vascular endothelial growth factor (VEGF) and EGFR. Combination of EGFR-TKI and ginsenoside Rg3 may be a promising strategy to delay acquired resistance. This retrospective study explored the efficacy and safety of this combined regimen in patients with EGFR mutation and advanced non-small cell lung cancer (NSCLC).

resultsBy the deadline of March 31th 2016, the median follow-up period reached 22.9 months. The median PFS was significantly longer in group A than in group B (12.4 months vs 9.9 months, P = 0.017). In addition, ORR was significantly higher in group A than in group B (59.6% vs 41.7%, P = 0.049). The median OS in group A showed no extended tendency compared with that in group B (25.4 months vs 21.4 months, P = 0.258). No significant difference in side effects was found between the two groups.

methodsA total of 124 patients with advanced NSCLC and EGFR active mutation were collected and analyzed. All of them were treated with first-line EGFR-TKI and divided into two groups. In group A (n=52), patients were administered EGFR-TKI plus ginsenoside Rg3 at standard doses. In group B (n=72), patients received EGFR-TKI alone. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR) and side effects were analyzed.

conclusionsGinsenoside Rg3 improves median PFS and ORR of first-line EGFR-TKI treatment in EGFR-mutant advanced NSCLC patients, thus providing a new regimen to delay acquired resistance of EGFR-TKI.

Indexed as

MutationAdultAgedAged, 80 and overAnorexiaAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungDisease-Free SurvivalErbB ReceptorsExanthemaFemaleGinsenosidesHumansLung NeoplasmsMaleMiddle AgedErbB Receptorsginsenoside Rg3GinsenosidesProtein Kinase InhibitorsVascular Endothelial Growth Factor Aadvanced NSCLCangiogenesisEGFR active mutationginsenoside Rg3targeted molecular therapy

Identifiers

PMID27655708
PMCPMC5342572
OpenAlexW2519439594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.